COMMUNIQUÉS West-GlobeNewswire

Sharecare to report fourth quarter and full year fiscal 2023 financial results on Thursday, March 28
27/03/2024
ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report fourth quarter and full year [...]
Rakovina Therapeutics Announces Strategic Pivot to AI
27/03/2024
Company Leveraging Deep Docking AI Drug Discovery Platform VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical [...]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27/03/2024
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions [...]
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27/03/2024
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
27/03/2024
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES- [...]
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
27/03/2024
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate [...]
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27/03/2024
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the [...]
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
27/03/2024
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
27/03/2024
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing [...]
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
27/03/2024
Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical [...]
Inventiva reports its 2023 full-year results
27/03/2024
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million 1 , and long-term deposit at €9.0 million [...]
Inventiva publie ses résultats annuels 2023
27/03/2024
Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022 Trésorerie et équivalents de trésorerie de 26,9 millions d’euros, dépôt à court terme de 0, [...]
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27/03/2024
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
BioSyent Announces Grant of Restricted Share Units
27/03/2024
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to [...]
By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada
27/03/2024
EDMONTON, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- Nearly 30,000 deaths from noncommunicable diseases in Canada in 2019, were due to high body mass index (BMI), most related to diabetes, cardiovascular disease, and [...]
Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group
27/03/2024
The network of physician-driven psychiatric practices continues to expand across the Southeastern United States to enhance patient care BATON ROUGE, La., March 27, 2024 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners , a [...]
American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results
27/03/2024
- Acquisition of 3 Rhode Island Radiation Therapy Cancer Centers progressing toward closing- - International Cancer Center equipment upgrade completed in Ecuador, Opening new Puebla, Mexico Center in Q2- - Lease [...]
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
27/03/2024
TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and [...]
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
27/03/2024
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the [...]

Pages